Company: SNWV
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050280
Chunk: 41

Company: SANUWAVE Health, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 41
---
797 Cash at End of Period$9,602 $3,259 Supplemental Information:Cash paid for interest$3,291 $3,189 Non-cash Investing and Financing Activities:Capitalize interest into senior secured debt549 3,850 Shares granted in lieu of board of director fees77 - Stock options granted in lieu of cash bonus117 - Right-of-use assets obtained in exchange for lease liabilities430 - Lease liabilities reduced upon lease modification99 - RSUs granted in exchange for services10 - Warrants issued in conjunction with convertible promissory notes - 3,633 Conversion of asset-backed secured promissory notes to convertible promissory notes- 4,584 Shares issued for settlement of debt- 1,412 Write off deferred merger costs- 1,226 

The accompanying notes to condensed consolidated financial statements are an integral part of these financial statements.

9

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2025

1.        Nature of the Business and Basis of Presentation

SANUWAVE Health, Inc. and subsidiaries (“SANUWAVE” or the “Company”) is focused on the commercialization of its patented regenerative medicine utilizing noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures.Basis of Presentation - The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all the information and disclosures required by U.S. GAAP for comprehensive financial statements. The financial information as of September 30, 2025, and for the three and nine months ended September 30, 2025, and 2024 is unaudited; however, in the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2025, are not necessarily indicative of the results that may be expected for any other interim period or for the year ending